JOURNAL OF THE CHINESE
CHEMICAL SOCIETY
Hantzsch Multicomponent Condensation
5.9 Hz, 1H), 6.17 (s, 1H), 6.21 (dd, J = 15.8, 5.9 Hz, 1H), 6.29 (d,
J = 15.8 Hz, 1H), 7.43-7.31 (m, 5H). 13C NMR (CDCl3, 62.9
MHz) d: 14.4, 19.5, 39.4, 59.7, 102.4, 121.4, 126.8, 128.0, 128.3,
130.5, 131.7, 137.7, 144.9, 167.2. FT-IR (KBr) nmax: 3336, 1691,
1645, 1488, 1218 cm-1.
Ethyl-5-(3-nitrophenyl)-2,7,7-trimethyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (5g)
M.p = 180-182 °C 1H NMR (250 MHz, CDCl3, DMSO-d6)
.
d: 0.97 (s, 3H, CH3), 1.13 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H),
2.17-2.30 (m, 4H), 2.51 (s, 3H), 4.10 (q, J = 7.1 Hz, 2H), 4.87 (s,
1H), 5.87 (s, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.69 (dt, J = 1.4, 7.9 Hz,
1H), 8.06-8.11, (m, 2H). 13C NMR (62.9 MHz, CDCl3, DMSO-d6)
d: 14.1, 19.3, 27.6, 32.2, 40.6, 43.5, 50.5, 59.9, 103.2, 112.8,
118.3, 122.3, 129.5, 134.4, 145.4, 148.5, 149.5, 157.9, 162.4,
195.9. FT-IR (KBr) nmax: 3618, 2318, 1689, 1523 cm-1.
Typical experimental procedure for the synthesis of
polyhydroquinolines 5a-q
A mixture of aldehyde (1mmol), ammonium acetate (4
mmol), dimedone (1 mmol) ethyl acetoacetate (1 mmol), and cad-
mium (II) nitrate (10 mol%), was refluxed in ethanol for the ap-
propriate time indicated in Table 3. After complete conversion as
indicated by TLC, the reaction mixture was cooled then poured
onto crushed ice, and extracted with ethyl acetate. The organic
layer was washed with brine, dried over sodium sulfate, and con-
centrated. The crude product was purified by recrystallization
from ethanol.
Ethyl-5-(3-chlorophenyl)-2,7,7-trimethyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (5i)
M.p = 236-238 °C. 1H NMR (200 MHz, CDCl3, DMSO-d6)
d: 0.95 (s, 3H), 1.05 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H), 2.01-2.21 (m,
4H), 2.40 (s, 3H), 4.05 (q, J = 7.2 Hz, 2H), 4.60 (s, 1H), 5.60 (s,
1H), 7.10-7.30 (m 4H). 13C NMR (62.9 MHz, CDCl3, DMSO-d6)
d: 14.4, 19.4, 26.6, 31.2, 40.4, 46.8, 52.9, 60.2, 103.3, 111.2,
125.9, 127.1, 128.7, 131.1, 132.3, 141.0, 149.5, 150.7, 167.5,
195.7. FT-IR (KBr) nmax: 3063, 2956, 1721, 1640 cm-1.
Spectroscopic data for selected compounds:
Ethyl 4-phenyl-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxylate (5a)
M.p = 202-204 °C. 1H NMR (250 MHz, CDCl3, DMSO-d6)
d: 0.94 (s, 3H), 1.08 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H), 2.14-2.33 (m,
4H), 2.38 (s, 3H), 4.05 (q, J = 7.1 Hz, 2H), 5.05 (s, 1H), 5.78 (s,
1H), 7.08-7.31 (m, 5H). 13C NMR (62.9 MHz, CDCl3, DMSO-d6)
d: 14.4, 19.4, 26.5, 31.2, 40.4, 46.8, 50.5, 59.5, 101.3, 111.2,
124.7, 128.6, 129.5, 137.6, 145.1, 149.5, 157.4, 162.7, 195.9.
FT-IR (KBr) nmax: 3290, 1698, 1612 cm-1.
REFERENCES
1. (a) Williams, D. A.; Foye, W. O.; Lemke, T. L. Foye’s Princi-
ples of Medicinal Chemistry; Lippincott Williams &
Wilkins: Philadelphia, 2002. (b) Eisenberg, M. J.; Brox, A.;
Bestawros, A. N. Am. J. Med. 2004, 116, 35. (c) Bossert, F.;
Meyer, H.; Wehinger, E. Angew. Chem. Int. Ed. 1981, 20,
762. (d) Nakayama, H.; Kasoaka, Y. Heterocycles 1996, 42,
901.
Ethyl 4-(4-methylphenyl)-2,7,7-trimethyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (5d)
M.p = 258-260 °C. 1H NMR (500 MHz, CDCl3 , DMSO-d6)
d: 0.95 (s, 3H), 1.07 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H), 2.12–2.22
(m, 4H), 2.25 (s, 3H), 2.36 (s, 3H), 4.09 (q, J = 7.1 Hz, 2H), 5.01
(s, 1H), 5.73 (s, 1H), 7.00 (d, J = 7.9 Hz, 2H), 7.18 (d, J = 7.9 Hz,
2H). 13C NMR (62.9 MHz, CDCl3, DMSO-d6) d: 14.1, 18.2, 20.9,
26.4, 32.1, 43.5, 50.2, 51.5, 58.9, 103.2, 110.1, 128.2, 128.3,
135.4, 139.8, 144.6, 149.1, 150.2, 166.9, 194.2. FT-IR (KBr): nmax
3275, 1702, 1647 cm-1.
2. Mauzeral, D.; Westheimer, F. H. J. Am. Chem. Soc. 1955, 77,
2261.
3. (a) Godfraid, T.; Miller, R.; Wibo, M. Pharmocol. Rev. 1986,
38, 321; (b) Sausins, A.; Duburs, G. Heterocycles 1988, 27,
269; (c) Mager, P. P.; Coburn, R. A.; Solo, A. J.; Triggle, D.
J.; Rothe, H. Drug Design Discovery 1992, 8, 273; (d)
Mannhold, R.; Jablonka, B.; Voigdt, W.; Schoenafinger, K.;
Schravan, K. Eur. J. Med. Chem. 1992, 27, 229.
4. (a) Klusa, V. Drugs Fut. 1995, 20, 135; (b) Bretzel, R. G.;
Bollen, C. C.; Maeser, E.; Federlin, K. F. Am. J. Kidney. Dis.
1993, 21, 53; (c) Bretzel, R. G.; Bollen, C. C.; Maeser, E.;
Federlin, K. F. Drugs Fut. 1992, 17, 465; (d) Boer, R.;
Gekeler, V. Drugs Fut. 1995, 20, 499.
Ethyl 4-(3-methylphenyl)-2,7,7-trimethyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (5e)
M.p = 256-258 °C. 1H NMR (250 MHz, CDCl3, DMSO-d6)
d: 0.97 (s, 3H, CH3), 1.05 (s, 3H), 1.23 (s, 3H), 1.21 (t, J = 7.1 Hz,
3H), 2.10-2.20 (m, 4H), 2.50 (s, 3H), 4.08 (q, J = 7.1 Hz, 2H), 4.98
(s, 1H), 5.65 (s, 1H), 6.95-7.15 (m, 4H). 13C NMR (62.9 MHz,
CDCl3, DMSO-d6) d: 14.2, 19.1, 21.5, 27.2, 28.9, 32.2, 35.9, 40.2,
50.4, 58.7, 103.8, 113.2, 120.1, 124.7, 137.6, 145.1, 157.4, 161.2,
162.7, 195.9. FT-IR (KBr) nmax: 2962, 2191, 1654, 1365 cm-1.
HRMS (ESI): m/z calcd for C22H27NO3Na: 376.18886 [M+Na]+,
found: 376.189.
5. Loev, B.; Snader, K. M. J. Org. Chem. 1965, 30, 1914.
6. Tu, S.-J.; Zhou, J.-F.; Deng, X.; Cai, P.-J.; Wang, H.; Feng,
J.-C. Chin. J. Org. Chem. 2001, 21, 313.
7. Sabitha, G.; Reddy, G. S. K. K.; Reddy, C. S.; Yadav, J. S. Tet-
rahedron Lett. 2003, 44, 4129.
8. Ji, S. J.; Jiang, Z. Q.; Lu, J.; Loh, T. P. Synlett 2004, 831.
9. (a) Breitenbucher, J. G.; Figliozzi, G. Tetrahedron Lett. 2000,
41, 4311. (b) Dondoni, A.; Massi, A.; Minghini, E.; Bertolasi,
V. Tetrahedron 2004, 60, 2311.
J. Chin. Chem. Soc. 2012, 59, 000-000
© 2012 The Chemical Society Located in Taipei & Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
5